Somewhat Favorable News Coverage Extremely Likely to Affect Conatus Pharmaceuticals (CNAT) Stock Price

News coverage about Conatus Pharmaceuticals (NASDAQ:CNAT) has trended somewhat positive this week, AlphaOne reports. The research group, a service of Accern, scores the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. AlphaOne ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Conatus Pharmaceuticals earned a news sentiment score of 0.03 on AlphaOne’s scale. AlphaOne also gave media stories about the biotechnology company an impact score of 100 out of 100, indicating that recent media coverage is extremely likely to have an impact on the company’s share price in the near term.

These are some of the media stories that may have impacted AlphaOne Sentiment Analysis’s analysis:

Insider Buying and Selling by Quarter for Conatus Pharmaceuticals (NASDAQ:CNAT)

Several brokerages have issued reports on CNAT. ValuEngine upgraded Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 24th. Stifel Nicolaus restated a “buy” rating and issued a $9.00 target price (up from $7.00) on shares of Conatus Pharmaceuticals in a report on Thursday, March 16th. Aegis reaffirmed a “buy” rating and issued a $11.00 price target on shares of Conatus Pharmaceuticals in a research note on Monday, May 15th. FBR & Co reaffirmed an “outperform” rating and issued a $16.00 price target on shares of Conatus Pharmaceuticals in a research note on Wednesday, March 15th. Finally, Zacks Investment Research raised Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, March 14th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Conatus Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $13.25.

Conatus Pharmaceuticals (NASDAQ CNAT) opened at 4.88 on Friday. The firm’s market cap is $127.70 million. Conatus Pharmaceuticals has a 52 week low of $1.45 and a 52 week high of $9.40. The stock has a 50 day moving average price of $5.87 and a 200 day moving average price of $5.05.

Conatus Pharmaceuticals (NASDAQ:CNAT) last issued its quarterly earnings results on Thursday, May 4th. The biotechnology company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.20. The company had revenue of $7 million during the quarter, compared to analyst estimates of $5.88 million. During the same period in the prior year, the business earned ($0.35) EPS. Equities research analysts expect that Conatus Pharmaceuticals will post ($0.70) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable News Coverage Extremely Likely to Affect Conatus Pharmaceuticals (CNAT) Stock Price” was reported by Transcript Daily and is the property of of Transcript Daily. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://transcriptdaily.com/2017/06/17/somewhat-favorable-news-coverage-extremely-likely-to-affect-conatus-pharmaceuticals-cnat-stock-price.html.

Conatus Pharmaceuticals Company Profile

Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.

Receive News & Ratings for Conatus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply